Campbell’s Downgraded as GLP-1 Adoption Hits 14%-15%, Margin Pressure Intensifies
CPB•Bernstein downgraded Campbell’s to Underperform, citing rising GLP-1 drug use among 14%–15% of U.S. adults and tougher regulations on artificial ingredients. It warned that changing preferences and margin pressure from higher packaging and freight costs, plus a San Francisco deceptive-marketing lawsuit, could further weigh on growth and profitability.
1. Bernstein Downgrade Details
Bernstein cut Campbell’s to Underperform as part of a broader sector downgrade highlighting structural headwinds. The firm cited weakening demand, slowing volume growth and competitive challenges in soups and snacks undermining the company’s outlook.
2. GLP-1 Adoption Impact
Accelerating use of GLP-1 weight-loss drugs—now reaching 14%–15% of U.S. adults versus 5.8% a year ago—is dampening consumption of carbohydrate-rich and sugary products, a core category for Campbell’s, while boosting demand for protein-focused alternatives.
3. Regulatory and Legal Challenges
New federal and state measures targeting artificial dyes, additives and ultra-processed foods, along with retailer mandates from Walmart and Target, require product reformulations. A San Francisco lawsuit alleging deceptive marketing of unhealthy products adds potential legal liabilities.
4. Margin Pressures and Cost Concerns
Higher packaging, freight and protein input costs are squeezing margins, prompting warnings that profitability may erode further. Elevated leverage also raises the possibility of dividend cuts if cash flows weaken.
